On September 16, Chargé d´Affaires Jennifer Bachus hosted a reception for U.S. biotech company Novavax during a recent visit of the company leadership from United States -Frank Czworka, Senior Vice President, Global Sales; Brian Rosen, Senior Vice President, Commercial Strategy;Kelly Cappio, VP for Policy & Government Affairs and their team.
Chargé Bachus remarked, “I applaud Novavax for choosing a facility in the Czech Republic to round out their supply chain. Novavax’s Czech subsidiary is located in Bohumil, Central Bohemia and conducts large-scale manufacturing of the key antigen component of their Covid-19 vaccine candidate. The acquisition of the manufacturing plant in Bohumil in 2020 was one of the largest American manufacturing investments in the Czech Republic – during a year of extreme economic uncertainty. We hope that their experience here will be a model for more high-value American investment and cooperation.”
Novavax is a U.S. biotech company founded in 1987 in Gaithersburg, Maryland. Novavax had been solely focused on vaccine development for several serious infectious diseases. With the rise of COVID and funding from the U.S. Government, the company redirected its efforts to focus on development and approval of a COVID-19 vaccine to add to global vaccination efforts. https://www.novavax.com
